Tag: Financing

 - Regina Hodits, Managing Director to join NUCLIDIUM’s Board of Directors

NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Compass Diversified (NYSE:CODI) on behalf of long-term stockholders following a class action complaint that was filed against Compass on June 6, 2025 with a Class Period from May 1, 2024, to May 7, 2025. Our investigation concerns whether the board of directors of Compass have breached their fiduciary duties to the company.

New York, NY, July 09, 2025 (GLOBE NEWSWIRE) -- YZi Labs, an investment vehicle fueling impact in Web3, AI, and biotech, today announced its support for 10X Capital, a leading investment firm focused on digital assets & digital asset treasury companies, in establishing the BNB Treasury Company, an independent U.S. initiative for digital asset treasury management on BNB Chain.

SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the XPLR Infrastructure class action lawsuit seeks to represent purchasers or acquirers of XPLR Infrastructure, LP f/k/a NextEra Energy Partners, LP (NYSE: XIFR) securities between September 27, 2023 and January 27, 2025, inclusive (the “Class Period”). Captioned Alvrus v. XPLR Infrastructure, LP f/k/a NextEra Energy Partners, LP, No. 25-cv-01755 (S.D. Cal.), the XPLR Infrastructure class action lawsuit charges XPLR Infrastructure, NextEra Energy, Inc., and certain of XPLR Infrastructure’s top former executives with violations of the Securities Exchange Act of 1934.

BASSETT, Va., July 09, 2025 (GLOBE NEWSWIRE) -- Bassett Furniture Industries, Inc. (Nasdaq: BSET) reported today its results of operations for its second quarter ended May 31, 2025.

Daix (France), New York City (New York, United States), July 9, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced a leadership transition with the appointment of Jason Campagna, MD, PhD, as President of Research and Development (“R&D”) and Chief Medical Officer (“CMO”) and Martine Zimmermann, PharmD, as Executive Vice President (“EVP”) of Regulatory Affairs and Quality Assurance.